Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?
admin 20th March 2018 Uncategorised 0Thanks to some positive new data, Roche finally has a chance to differentiate itself in the immuno-oncology market for lung cancer, now dominated by Merck & Co. and its rival med Keytruda. But it’s unclear whether that opportunity can translate into significant sales.
More: Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?
Source: fierce